on-invasive Measurement of Hepatic Fibrosis in Patients Using Methotrexate.

Recruiting

• Conditions: Liver damage en Liver disease; 10019654; 10023213

• Registration Number: NL-OMON30803
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 1600

Inclusion Criteria

- Patiënts with Rheumatoid Arthritis
- Use of Methotrexate
- Disturbance of liver enzymes > 1,7 times upper limit
- > 18 years.

Exclusion Criteria

< 18 years
- Failure of measurements with elastography

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Non-invasive Assessment of Fibrosis or Cirrhosis during treatment with<br /><br>Methotrexate in patients with Rheumatoid Arthritis and/or Psoriasis with the<br /><br>Fibroscan.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Incidence of liver enzyme disturbances in patients treated with Methotrexate<br /><br>for Rheumatoid Arthritis and Psoriasis.<br /><br>Incidence of Fibrosis or Cirrhosis in patients treated with Methotrexate for<br /><br>Rheumatoid Arthritis and Psoriasis.</p><br>